Fuse Expands Global Distribution of Flip Testing Platform
Fuse Diagnostics Ltd (Fuse) has today announced a significant expansion in its market presence following the signing of a number of distribution agreements in key target markets for it’s Flip product range, including it’s rapid Mycoplasma test kit Flip Mycoplasma.
Fuse’s distribution network now encompasses;
UK and Ireland - Cambridge Biosciences (Stratech)
Denmark, Norway & Sweden - You Do Bio
Spain and Portugal - Abyntek
Europe (Other) - Clinisciences
Israel - Tamar
New Zealand - Ngaio
China - Amyjet Scientific
US - Labscoop
Fuse also sells direct in many territories.
Flip Mycoplasma is a revolutionary new test kit that detects cell culture contamination with unrivalled speed, accuracy and simplicity. It delivers laboratory PCR quality results in just 12 minutes in a simple, single-use format, enabling ultra-rapid detection of Mycoplasma contamination in cell cultures.
Flip Mycoplasma is provided in a ready-to-use format and exhibits exceptional diagnostic performance giving a clear visual result read-out in just minutes without any complex equipment or processing. It empowers end users to eliminate reproducibility and quality issues in cell biology research and bioprocessing - saving valuable time and reducing costs.
Fuse CEO Dr Harry Lamble said: “We are thrilled to expand the availability of the Flip platform across the world with this new range of distributor partnerships, as a company we have always had a global vision”
Flip sales have continued to grow and has seen Flip Mycoplasma adopted into world leading labs at a large number of leading institutions and businesses across the UK and US. With this new announcement the company anticipates further significant growth across international markets.
ENDS
Notes for editors
Fuse Diagnostics is focused on delivering laboratory-quality diagnostic information wherever it is needed through innovative, rapid, low-cost tests – addressing the cost and performance challenges of established approaches. The company is developing a revolutionary new generation of multianalytic diagnostic products, based on its Flip and Apex platforms, to make accurate point-of-need testing a reality for all. Fuse founders Harry and Ralph Lamble previously founded Sense Biodetection where they developed the world’s first rapid instrument-free, molecular diagnostic test (Veros COVID-19) during the pandemic. Following the acquisition of Sense by Sherlock Biosciences in 2023, the brothers decided to apply their experience of clinical product development and commercialisation to address the widespread demand for rapid onsite pathogen testing across industry.
Flip Mycoplasma is a new test for mycoplasma contamination in cell culture that allows users to screen their cultures, cell lines and reagents with unrivalled speed, accuracy and simplicity. It is highly accurate and targets 16S ribosomal RNA for robust specificity, delivering the performance of laboratory PCR in just minutes. It is simple to use, with ambient storage and is provided in a ready-to-use format. Samples can be tested directly without processing and the test gives a clear visual result readout. Flip Mycoplasma is a versatile solution, compatible with any standard heat block or PCR machine, or the USB-C powered Flip Nest, and allows users to perform rapid molecular quality testing in any location without complex equipment or procedures.